[go: up one dir, main page]

Groves et al., 2020 - Google Patents

Multicenter evaluation of the Quantra QPlus system in adult patients undergoing major surgical procedures

Groves et al., 2020

View HTML
Document ID
11841750516721993705
Author
Groves D
Welsby I
Naik B
Tanaka K
Hauck J
Greenberg C
Winegar D
Viola F
Publication year
Publication venue
Anesthesia & Analgesia

External Links

Snippet

BACKGROUND: The management of perioperative bleeding and the optimization of the available therapies are subjects of significant clinical interest. Clinical guidelines recommend the use of whole blood viscoelastic testing devices to target the utilization of …
Continue reading at journals.lww.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data

Similar Documents

Publication Publication Date Title
Groves et al. Multicenter evaluation of the Quantra QPlus system in adult patients undergoing major surgical procedures
Dias et al. Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: Implications for trauma and acute care surgery
Bonar et al. Overview of hemostasis and thrombosis and contribution of laboratory testing to diagnosis and management of hemostasis and thrombosis disorders
De Lange et al. Peri-partum reference ranges for ROTEM® thromboelastometry
Görlinger et al. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability
Dunham et al. TEG® and RapidTEG® are unreliable for detecting warfarin-coagulopathy: a prospective cohort study
Brown et al. Ability of thromboelastography to detect hypercoagulability: a systematic review and meta-analysis
Huffmyer et al. Comparison of SEER sonorheometry with rotational thromboelastometry and laboratory parameters in cardiac surgery
Schlimp et al. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry
Eby Novel anticoagulants and laboratory testing
Lentschener et al. Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study
Reynolds et al. A comparison of a new ultrasound-based whole blood viscoelastic test (SEER sonorheometry) versus thromboelastography in cardiac surgery
Ranucci et al. Platelet contribution to clot strength in thromboelastometry: Count, function, or both?
Dempfle et al. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots
Holland et al. Should plasma be transfused prophylactically before invasive procedures?
Naik et al. SEER sonorheometry versus rotational thromboelastometry in large volume blood loss spine surgery
Penk et al. Bleeding and thrombosis with pediatric extracorporeal life support: A roadmap for management, research, and the future from the Pediatric Cardiac Intensive Care Society: Part 2
Raspé et al. Rotational thromboelastometry for assessing bleeding complications and factor XIII deficiency in cardiac surgery patients
Welsh et al. Thromboelastography is a suboptimal test for determination of the underlying cause of bleeding associated with cardiopulmonary bypass and may not predict a hypercoagulable state
Hartmann et al. Thromboelastography (TEG) point-of-care diagnostic for hemostasis management
Chandler Emergency assessment of hemostasis in the bleeding patient
Naik et al. Prediction of hypofibrinogenemia and thrombocytopenia at the point of care with the Quantra® QPlus® System
Othman et al. The use of viscoelastic hemostatic tests in pregnancy and puerperium: review of the current evidence‐communication from the Women's Health SSC of the ISTH
Zghaibe et al. Clinical utility of the Quantra® point‐of‐care haemostasis analyser during urgent cardiac surgery
Rimac et al. Is it acceptable to use coagulation plasma samples stored at room temperature and 4° C for 24 hours for additional prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin, and D‐dimer testing?